Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia

Neuropsychiatry

Volumn 1, Issue 3, 2011, Pages 275-289

  Olivares, José M ^a   Pinal, Beatriz ^a   Cinos, Carmen ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUSPIRILENE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PENFLURIDOL; PERPHENAZINE; PERPHENAZINE ENANTHATE; PIMOZIDE; PIPOTIAZINE PALMITATE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITALIZATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84866979349     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.11.24     Document Type: Review

References (165)

1. Freedman R: Schizophrenia. N. Engl. J. Med. 349, 1738-1749 (2003). (Pubitemid 37315012)
2. Delay J, Deniker P: Trente-huit cas de psychoses traits par le cure prolongé et continue de 4560RP. Le Congrès des Al. Et Neurol. De Langue Fr. Presented at: Comptes Rendus du Congres Paris. Masson, France (1952).
3. Davis JM, Matalon L, Watanabe MD et al.: Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773 (1994).
4. Dencker SJ: The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J. Clin. Psychiatry 45, 22-27 (1984). (Pubitemid 14116750)
5. Barnes TR, Curson DA: Long-term depot antipsychotics. A risk-benefit assessment. Drug. Saf. 10, 464-479 (1994). (Pubitemid 24191869)
6. Ereshefsky L, Saklad SR, Jann MW et al.: Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J. Clin. Psychiatry 45, 50-59 (1984). (Pubitemid 14116754)
7. Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrics toward antipsychotic depot medication. J. Clin. Psychiatry 67, 1948-1953 (2006). (Pubitemid 46048193)
8. Szasz T: Where does psychiatry go? In: Ideology and Insanity. Essays on the Psychiatric Dehumanization of Man. Szasz T (Ed.). Anchor Books, New York, NY, USA, 213-238 (1970).
9. Postel J, Quetel Cl, El siglo XX: Fondo de Cultura económica. In: Historia de la Psiquiatría. Postel J, Quetel Cl (Eds). Mexico, 457-571 (1987). Translated from: Nouvelle Histoire de la Psychiatrie. Privat, Toulouse, France (1983).
10. Johnson DAW, Freeman HL: Long-acting tranquillisers. Practitioner 208, 395-400 (1972).
11. Davis JM: Overview: maintenance therapy in schizophrenia. Am. J. Psychiatry 132, 1237-1245 (1975).
12. Quitkin F, Rifkin A, Kane J, Ramos-Lorenzi JR, Klein DF: Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics. Arch. Gen. Psychiatry. 35(7), 889-892 (1978). (Pubitemid 9076802)
13. Wistedt B: A neuroleptic withdrawal study in chronic schizophrenic patients. Acta Psychiatr. Scand. 64, 65-84 (1981).
14. Gerlach J, Koppelhus P, Helweg E, Monrad A: Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr. Scand. 50(4), 410-424 (1974).
15. Simpson GM, Varga E: Clozapine: a new antipsychotic agent. Curr. Ther. Res. Clin. Exp. 16(7), 679-686 (1974).
16. Matz R, Rick W, Thompson H, Gershon S: Clozapine: a potential antipsychotic agent without extrapyramidal manifestations. Curr. Ther. Res. Clin. Exp. 16(7), 687-695 (1974).
17. Schanda H, Stompe T: Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based? Neuropsychiatr. 24(1), 14-26 (2010).
18. Kane JM: Treatment adherence and long-term outcomes. CNS Spectr. 12, 21-26 (2007). (Pubitemid 350099581)
19. Leucht S, Heres S: Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J. Clin. Psychiatry 67(5), 3-8 (2006). (Pubitemid 43837695)
20. Ayuso-Gutierrez JL, Rio JM: Factors influencing relapse in the long-term course of schizophrenia. Schizophr. Res. 28, 199-206 (1997). (Pubitemid 28055667)
21. Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr. Bull. 21, 419-429 (1995).
22. Zygmunt A, Olfson M, Boyer CA, Mechanic D: Interventions to improve medication adherence in schizophrenia. Am. J. Psychiatry 159, 1653-1664 (2002).
23. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63, 892-909 (2002). (Pubitemid 35231730)
24. Perkins DO: Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63, 1121-1128 (2002). (Pubitemid 36084056)
25. Patel MX, David AS: Why aren't depot antipsychotics prescribed more often, and what can be done about it? Adv. Psychiatr. Treat. 11, 203-213 (2005). (Pubitemid 40691689)
26. Budd RJ, Hughes IC, Smith JA: Health beliefs and compliance with antipsychotic medication. Br. J. Clin. Psychol. 35, 393-397 (1996). (Pubitemid 26320876)
27. Smith J, Hughes ICT, Budd RJ: Non-compliance with antipsychotic medication. User's view on advantages and disadvantages. J. Ment. Health 8, 287-296 (1999). (Pubitemid 29305581)
28. Hamann J, Langer B, Leucht S et al.: Medical decision making in antipsychotic drug choice for schizophrenia. Am. J. Psychiatry 161, 1301-1304 (2004). (Pubitemid 38859185)
29. Heres S, Hamann J, Mendel R et al.: Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1987-1993 (2008).
30. Kane J, Garcia-Ribera C: Clinical guideline recommendations for antipsychotic long-acting injections. Br. J. Psychiatry 195, S63-S67 (2009).
31. Glazer WM: The depot paradox. Behav. Health 27, 44-46 (2007).
32. Adams CE, Fenton MKP, Quraishi S, David AS: Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 179, 290-299 (2001). (Pubitemid 32996037)
33. Arango C, Bombin I, Gonzalez-Salvador T, Garcia-Cabeza I, Bobes J: Randomized clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur. Psychiatry 21, 34-40 (2006). (Pubitemid 43245596)
34. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S: Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomized long-terms trials. Schizophr. Res. 127(1-3), 83-92 (2011).
35. Del Giudice J, Clark WG, Gocka EF: Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16, 32-36 (1975).
36. Rifkin A, Quitkin F, Rabiner CJ, Klein DF: Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch. Gen. Psychiatry 34, 43-47 (1977). (Pubitemid 8023182)
37. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E: Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psychiatry 36, 1283-1294 (1979). (Pubitemid 11145664)
38. Schooler NR, Levine J, Severe JB et al.: Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch. Gen. Psychiatry 37, 16-24 (1980). (Pubitemid 10139118)
39. Falloon I, Watt DC, Shepherd M: A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol. Med. 8, 59-70 (1978). (Pubitemid 8266864)
40. Barnes TR, Milavic G, Curson DA, Platt SD: Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine. Soc. Psychiatry 18, 193-199 (1983). (Pubitemid 14234083)
41. Li R, Zhang M, Shi S: The effect of haloperidol decanoate on negative and positive symptoms of schizophrenia. Chin. J. Nerv. Ment. Diseases 22, 9-12 (1996).
42. Conley RR, Kelly DL, Love RC, McMahon RP: Rehospitalization risk with second-generation and depot antipsychotics. Ann. Clin. Psychiatry 15, 23-31 (2003). (Pubitemid 36723638)
43. Tiihonen J, Walhbeck L, Lönnqvist J et al.: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333, 224-227 (2006). (Pubitemid 44406713)
44. Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M: Remission and relapse in outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J. Clin. Psychopharmacol. 26, 571-578 (2006). (Pubitemid 44772733)
45. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D: Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur. Neuropsychopharmacol. 17, 235-244 (2007). (Pubitemid 46164772)
46. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR: Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr. Serv. 59, 315-317 (2008).
47. Devito RA, Brink L, Sloan C, Jolliff F: Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by reduction in hospital readmissions. J. Clin. Psychiatry 39, 26-34 (1978).
48. Marchiaro L, Rocca P, LeNoci F et al.: Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. J. Clin. Psychiatry 66, 1423-1431 (2005). (Pubitemid 41779541)
49. Denham J, Adamson L: The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr. Scand. 47, 420-430 (1971).
50. Gottfries CG, Green L: Flupenthixol decanoate in treatment of out patients. Acta Psychiatr. Scand. Suppl. 255, 15-24 (1974).
51. Morrit C: Long acting phenothiazines and schizophrenia. Nurs. Mirror Midwives J. 138, 57-59 (1974).
52. Johnson DAW: Observations on the dose regime of fluphenazine decanoate in maintenance therapy of schizophrenia. Br. J. Psychiatry 126, 457-461 (1975).
53. Lindholm H: The consumption of inpatient psychiatric resources prior to and during treatment with a depot neuroleptic, perphenazine enanthate. A mirror study. Nord. Psykiatr. Tidsskr. 29, 513-520 (1975).
54. Marriott P, Hiep A: A mirror image out-patient study at a depot phenothiazine clinic. Aust. NZ J. Psychiatry 10, 163-167 (1976).
55. Polonowita A, James NM: Fluphenazine decanoate maintenance in schizophrenia: a retrospective study. NZ Med. J. 83, 316-318 (1976).
56. Freeman H: Twelve yearś experience with the total use of depot neuroleptics in a defined population. Adv. Biochem. Psychopharmacol. 24, 559-564 (1980).
57. Tan CT, Ong TC, Chee KT: The use of fluphenazine decanoate (Modecate) depot therapy in outpatient schizophrenics-a retrospective study. Singapore Med. J. 22, 214-218 (1981). (Pubitemid 12105862)
58. Tegeler J, Lehmann E: A follow-up study of schizophrenic outpatients treated with depot-neuroleptics. Prog. Neuropsychopharmacol. 5, 79-90 (1981). (Pubitemid 11066665)
59. Keks NA, Ingham M, Khan A, Karcher K: Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br. J. Psychiatry 191, 131-139 (2007). (Pubitemid 47204533)
60. Houthoofd SA, Morrens M, Sabbe BG: Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin. Ther. 30(9), 1565-1589 (2008).
61. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM: A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J. Clin. Psychiatry 70(10), 1397-1406 (2009).
62. Gaebel W, Schreiner A, Bergmans P et al.: Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35(12), 2367-2377 (2010).
63. De Graeve D, Smet A, Mehnert A et al.: Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 23(Suppl. 1), 35-47 (2005).
64. Edwards NC, Locklear JC, Rupnow MF, Diamond RJ: Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 23(Suppl. 1), 75-89 (2005).
65. Kim B, Lee SH, Choi TK et al.: Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(5), 1231-1235 (2008).
66. Olivares JM, Rodriguez-Morales A, Diels J et al.: Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur. Psychiatry 24(5), 287-296 (2009).
67. Gutiérrez-Casares JR, Cañas F, Rodríguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D: Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study. CNS Spectr. 15(5), 327-337 (2010).
68. Chue P, Eerdekens M, Augustyns I et al.: Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 15(1), 111-117 (2005). (Pubitemid 39574406)
69. Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ: Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr. Q. 80(4), 241-249 (2009).
70. Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P: Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health 12(Suppl. 3), S66-S69 (2009).
71. Taylor M, Currie A, Lloyd K, Price M, Peperell K: Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J. Psychopharmacol. 22(2), 128-131 (2008). (Pubitemid 351322859)
72. Fuller M, Shermock K, Russo P et al.: Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J. Med. Econ. 12(4), 317-324 (2009).
73. Su KP, Chang HC, Tsai SJ, Yen FC, Tang CH: Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value Health 12(Suppl. 3), S118-S121 (2009).
74. Di Lorenzo R, Fiorini F, Santachiara S: The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study. Psychopharmacol. Bull. 43(1), 39-52 (2010).
75. Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R: Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int. J. Clin. Pharmacol. Ther. 46(1), 14-22 (2008).
76. Marinis TD, Saleem PT, Glue P et al.: Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 40(6), 257-263 (2007). (Pubitemid 350232817)
77. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ: Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int. J. Neuropsychopharmacol. 8(3), 427-438 (2005). (Pubitemid 41002496)
78. Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER: Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J. Psychopharmacol. 9(5 Suppl.), 32-38 (2005). (Pubitemid 41392295)
79. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M: Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J. Clin. Psychiatry 65(8), 1084-1089 (2004).
80. van Os J, Bossie CA, Lasser RA: Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int. Clin. Psychopharmacol. 19(4), 229-232 (2004). (Pubitemid 38901651)
81. Llorca PM, Bouhours P, Moreau-Mallet V: French investigators group. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale 34(2), 170-178 (2008). (Pubitemid 351621977)
82. Curtis VA, Katsafouros K, Möller HJ, Medori R, Sacchetti E: Long-acting risperidone improves negative symptoms in stable psychotic patients. J. Psychopharmacol. 22(3), 254-261 (2008). (Pubitemid 351847446)
83. Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG: Risperidone Long-Acting Trial Investigators (R-LAI). Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum. Psychopharmacol. 24(7), 574-583 (2009).
84. Kim SW, Shin IS, Kim JM et al.: Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum. Psychopharmacol. 24(7), 565-573 (2009).
85. Schmauss M, Diekamp B, Gerwe M, Schreiner A, Ibach B: Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? Pharmacopsychiatry 43(2), 73-80 (2010).
86. Verma S, Subramaniam M, Abdin E et al.: Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients. Hum. Psychopharmacol. 25(3), 230-235 (2010).
87. Lloyd K, Latif MA, Simpson S, Shrestha KL: Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum. Psychopharmacol. 25(3), 243-252 (2010).
88. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A: Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur. Psychiatry 25(4), 220-229 (2010).
89. Carswell C, Wheeler A, Vanderpyl J, Robinson E: Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin. Drug Investig. 30(11), 777-787 (2010).
90. Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U: The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur. J. Health Econ. 11(6), 585-594 (2010).
91. Girardi P, Serafini G, Pompili M, Innamorati M, Tatarelli R, Baldessarini RJ: Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 43(2), 66-72 (2010).
92. Niaz OS, Haddad PM: Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr. Scand. 16(1), 36-46 (2007). (Pubitemid 46889775)
93. Leal A, Rosillon D, Mehnert A, Jarema M, Remington G: Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol. Drug Saf. 13(11), 811-816 (2004). (Pubitemid 39496905)
94. Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V: Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr. Scand. 120(2), 97-101 (2009).
95. Young CL, Taylor DM: Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr. Scand. 114(1), 14-20 (2006). (Pubitemid 43885480)
96. Owen RT: Olanzapine: a review of rapid and long-acting parenteral formulations. Drugs Today (Barc.) 46(3), 173-181 (2010).
97. Lindenmayer J: Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr. Dis. Treat. 24(6), 261-267 (2010).
98. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D: An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J. Clin. Psychiatry 69(5), 790-799 (2008). (Pubitemid 351838688)
99. Kane JM, Detke HC, Naber D et al.: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am. J. Psychiatry 167(2), 181-189 (2010).
100. Mamo D, Kapur S, Keshavan M et al.: D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 33(2), 298-304 (2008). (Pubitemid 350243350)
101. Detke HC, McDonnell DP, Brunner E et al.: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10, 10-43 (2010).
102. McDonnell DP, Detke HC, Bergstrom RF et al.: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 10, 44-45 (2010).
103. Hoy SM, Scott LJ, Keating GM: Intramuscular paliperidone palmitate. CNS Drugs 24(3), 227-244 (2010).
104. Bishara D: Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr. Dis. Treat. 6, 561-572 (2010).
105. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D: A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J. Psychopharmacol. 25(5), 685-697 (2011).
106. Nasrallah HA, Gopal S, Gassmann-Mayer C et al.: A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35(10), 2072-2082 (2010).
107. Pandina GJ, Lindenmayer JP, Lull J et al.: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J. Clin. Psychopharmacol. 30(3), 235-244 (2010).
108. Gopal S, Hough DW, Xu H et al.: Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int. Clin. Psychopharmacol. 25(5), 247-256 (2010).
109. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M: Paliperidone palmitate maintenance treatment in delaying the time-to relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 116(2-3), 107-117 (2010).
110. Kramer M, Litman R, Hough D et al.: Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int. J. Neuropsychopharmacol. 13(5), 635-647 (2010).
111. Pandina G, Lane R, Gopal S et al.: A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(1), 218-226 (2010).
112. Engelhardt DM, Rosen B, Freedman N, Margolis R: Phenothiazines in prevention of psychiatric hospitalization. Delay or prevention of hospitalization-a reevaluation. Arch. Gen. Psychiatry 16, 98-101 (1967).
113. Itil T, Keskiner A: Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis. Dis. Nerv. Syst. 31(Suppl.), 37-42 (1970).
114. Freedman R: Schizophrenia. N. Engl. J. Med. 349, 1738-1749 (2003). (Pubitemid 37315012)
115. Delay J, Deniker P: Trente-huit cas de psychoses traits par le cure prolongé et continue de 4560RP. Le Congrès des Al. Et Neurol. De Langue Fr. Presented at: Comptes Rendus du Congres Paris. Paris, France (1952).
116. Davis JM, Matalon L, Watanabe MD et al.: Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773 (1994).
117. Dencker SJ: The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J. Clin. Psychiatry 45, 22-27 (1984). (Pubitemid 14116750)
118. Stahl SM: Does evidence from clinical trials in psychopharmacology apply in clinical practice? J. Clin. Psychiatry 62(1), 6-7 (2001). (Pubitemid 32154310)
119. March J, Silva SG, Compton S, Shapiro M, Califf R, Krishna R: The Case for Practical Clinical Trials in Psychiatry. Am. J. Psychiatry 162, 836-846 (2005). (Pubitemid 40676194)
120. Haddad PM, Taylor M, Niaz O: First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of Randomized controlled trials and observational studies. Br. J. Psychiatry 195, S20-S28 (2009).
121. Labelle A, Bourget D, Boulay LJ, Ellis J, Tessier P: Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. J. Clin. Psychopharmacol. 22(6), 545-553 (2002). (Pubitemid 35416779)
122. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 160(6), 1125-1132 (2003). (Pubitemid 41070972)
123. Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L: Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int. Clin. Psychopharmacol. 25(3), 149-154 (2010).
124. De la Gándara J, San Molina L, Rubio G, Rodriguez-Morales A, Hidalgo Borrajo R, Burón JA: Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. Expert. Rev. Neurother. 9(10), 1463-1474 (2009).
125. Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S: Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur. Neuropsychopharmacol. 17(2), 138-144 (2007). (Pubitemid 44779189)
126. Docherty JP, Bossie CA, Lachaux B et al.: Patient-based and clinician-based support for the remission criteria in schizophrenia. Int. Clin. Psychopharmacol. 22(1), 51-55 (2007). (Pubitemid 44950768)
127. Möller HJ: Long-acting risperidone: focus on safety. Clin. Ther. 28(5), 633-651 (2006).
128. Parellada E: Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations. Psychopharmacol. Bull. 40(2), 82-100 (2007)
129. Kissling W, Glue P, Medori R, Simpson S: Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum. Psychopharmacol. 22(8), 505-513 (2007).
130. Kim SW, Kim KM, Kim JM et al.: Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(2), 543-545 (2007).
131. Kane J: Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J. Clin. Psychiatry 67(Suppl. 5), 9-14 (2006). (Pubitemid 43837696)
132. Valenstein M, Ganoczy D, McCarthy JF et al.: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J. Clin. Psychiatry 67, 1542-1550 (2006). (Pubitemid 44787436)
133. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G: Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J. Clin. Psychiatry 62(11), 855-859 (2001). (Pubitemid 33131171)
134. Wisted B: How does the psychiatric patient feel about depot treatment, compulsion or help? Nord. J. Psychiatry 49(Suppl. 35), 41-46 (1995).
135. Levine J, Schooler NR, Cassano GB: The role of depot neuroleptics in the treatment of schizophrenic patients. Psychol. Med. 9, 383-386 (1979). (Pubitemid 9198807)
136. Bachmann S, Bottmer C, Schroder J: One-year outcome and its prediction in first-episode schizophrenia-a naturalistic study. Psychopathology 41, 115-123 (2008). (Pubitemid 350308312)
137. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J: Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J. Clin. Psychopharmacol. 28(2), 210-213 (2008). (Pubitemid 351419182)
138. Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS: Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr. Med. Res. Opin. 25 (9), 2197-2206 (2009).
139. Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; On behalf of the e-STAR Study Group: Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12-and 24-month follow-up from the e-STAR database in Spain. Appl. Health Econ. Health Policy 6(1), 41-53 (2008)
140. Patel MX, Taylor M, David AS: Antipsychotic long-acting injections: mind the gap. Br. J. Psychiatry Suppl. 52, S1-S4 (2009).
141. Barnes TR, Shingleton-Smith A, Paton C: Antipsychotic long-acting injections: prescribing practice in the UK. Br. J. Psychiatry Suppl. 52, S37-S42 (2009).
142. Rothbard AB, Kuno E, Foley K: Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr. Bull. 29, 531-540 (2003). (Pubitemid 37339387)
143. Paton C, Barnes TRE, Cavanagh MR, Taylor D, Lelliott P; the POMH-UK project team: High-dose and combination antipsychotic prescribing in acute adult wards in the UK; the challenges posed by p.r.n. prescribing. Br. J. Psychiatry 192, 435-439 (2008). (Pubitemid 351809896)
144. Barnes TRE, Paton C, Cavanagh MR, Hancock E, Taylor DM: A UK audit of sceening for the metabolic side effects of antipsychotics in community patients. Schizophr. Bull. 33, 1397-1401 (2007).
145. Barnes TRE, Paton C, Hancock E, Cavanagh MR, Taylor DM, Lelliott P: Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr. Scand. 118, 26-33 (2008). (Pubitemid 351832021)
146. Kane JM, Aguglia E, Altamura AC et al.: Guidelines for depot antipsychotic treatment in schizophrenia. Eur. Neuropsychopharmacol. 8(1), 55-66 (1998). (Pubitemid 28012861)
147. Jaeger M, Rossler W: Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 175(1-2), 58-62 (2010).
148. Patel MX, De Zoysa N, Bernadt M, David A: Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J. Psychopharmacol. 23, 789-796 (2009).
149. Besenius C, Clarck-Carter D, Nolan, P: Health professionals' attitudes to depot injection antipsychotic medication: a systematic review. J. Psychiatr. Ment. Health Nurs. 17, 452-462 (2010).
150. Emsley R, Oosthuizen P, Koen L et al.: Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int. Clin. Psychopharmacol. 23, 325-331 (2008).
151. Heres S, Schmitz FS, Leucht S, Pajonk FG: The attitude of patients towards antipsychotic depot treatment. Int. Clin. Psychopharmacol. 22, 275-282 (2007). (Pubitemid 47237546)
152. Waddell L, Taylor M: Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br. J. Psychiatry Suppl. 52, S43-S50. (2009).
153. David A, Quraishi S, Rathbone J: Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst. Rev. 3, CD001717 (2005).
154. David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J: Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst. Rev. 1, CD000307 (2005).
155. Abhijnhan A, Adams CE, David A, Ozbilen M: Depot fluspirilene for schizophrenia. Cochrane Database Syst. Rev. 24(1), CD001718 (2007).
156. Quraishi S, David A, Adams CE: Depot bromperidol decanoate for schizophrenia. Cochrane Database Syst. Rev. 2, CD001719 (2000).
157. Quraishi S, David A: Depot fluspirilene for schizophrenia. Cochrane Database Syst. Rev. 2, CD001718 (2000).
158. Quraishi S, David A: Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst. Rev. 2, CD001717 (2000).
159. Quraishi S, David A: Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Database Syst. Rev. 2, CD001470 (2000).
160. Lai YC, Huang MC, Chen CH, Tsai CJ, Pan CH, Chiu CC: Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. Psychiatry Clin. Neurosci. 63(4), 440-448 (2009).
161. Martinez-Gras I, Rubio G, del Manzano BA et al.: The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone. Schizophr. Res. 115(2-3), 215-221 (2009).
162. Hensen M, Heeg B, Löthgren M, van Hout B: Cost effectiveness of long-acting risperidone in Sweden. Appl. Health Econ. Health Policy 8(5), 327-341 (2010).
163. Surguladze SA, Chu EM, Marshall N et al.: Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. J. Psychopharmacol. DOI: 10.1177/0269881110363316 (2010) (Epub ahead of print).
164. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ: Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Clin. Ther. 32(1), 108-118 (2010).
165. Johnson DA: Historical perspective on antipsychotic long-acting injections. Br. J. Psychiatry Suppl. 52, S7-S12 (2009).